This segment focuses on the research, development, and commercialization of immunoassay products. Autobio offers a range of automated and semi-automated immunoassay analyzers, including the AutoLumo A2000 Plus, as well as microplate readers and washers. R&D activities include the development of new reagents and assays for various disease areas, such as infectious diseases, oncology, and endocrinology. Technologies employed include chemiluminescence immunoassay (CLIA) and enzyme-linked immunosorbent assay (ELISA). These products are used in clinical laboratories to aid in the diagnosis and monitoring of various health conditions, impacting patient outcomes by providing accurate and timely results. Autobio's market positioning is strong in China, with a focus on expanding globally. Future opportunities lie in the development of new biomarkers and assays, as well as the integration of automation and data analytics. Regulatory compliance and clinical validation are critical aspects of this segment, ensuring the safety and efficacy of the products. Partnerships with other companies are also important for expanding market reach and product offerings.

This segment is dedicated to the development, production, and distribution of microbiology diagnostic products. Autobio's offerings include automated blood culture systems, blood culture bottles, and other related products. R&D efforts are focused on improving the speed, accuracy, and efficiency of microbial identification and antibiotic susceptibility testing. Technologies used include automated blood culture systems and rapid diagnostic tests. These products are crucial for the diagnosis and management of infectious diseases, impacting patient care by enabling timely and appropriate treatment decisions. Autobio aims to be a leading provider of microbiology diagnostic solutions in China and globally. Future growth opportunities include the development of new tests for emerging pathogens and the integration of molecular diagnostics. Regulatory compliance and clinical validation are essential for ensuring the reliability and performance of these products. Collaborations with hospitals and research institutions are important for clinical trials and market expansion.

This segment focuses on the development, manufacturing, and commercialization of biochemistry diagnostic reagents and instruments. Autobio offers a range of products used in clinical chemistry for the analysis of various analytes in blood and other bodily fluids. R&D activities include the development of new reagents and assays, as well as the improvement of existing products. Technologies used include automated chemistry analyzers and spectrophotometry. These products are essential for routine clinical testing, aiding in the diagnosis and monitoring of a wide range of diseases, impacting patient outcomes by providing critical information for clinical decision-making. Autobio aims to provide high-quality and reliable biochemistry diagnostic solutions. Future opportunities include the development of new tests for emerging diseases and the integration of automation and data analytics. Regulatory compliance and clinical validation are critical aspects of this segment. Partnerships with clinical laboratories and healthcare providers are important for market access and product adoption.